# Iressa Expanded Access Program (EAP)

> **NCT00034879** · PHASE3 · COMPLETED · sponsor: **AstraZeneca**

## Conditions studied

- Carcinoma
- Non-small-cell Lung
- Metastases
- Neoplasm

## Interventions

- **DRUG:** ZD1839 (Gefitinib)

## Key facts

- **NCT ID:** NCT00034879
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2003-10
- **Final completion:** 2003-10
- **Target enrollment:** — (—)
- **Last updated:** 2013-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00034879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00034879, "Iressa Expanded Access Program (EAP)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00034879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*